Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation
- PMID: 38776184
- PMCID: PMC11822724
- DOI: 10.1097/HEP.0000000000000933
Low MBOAT7 expression, a genetic risk for MASH, promotes a profibrotic pathway involving hepatocyte TAZ upregulation
Abstract
Background and aims: The common genetic variant rs641738 C>T is a risk factor for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASH), including liver fibrosis, and is associated with decreased expression of the phospholipid-remodeling enzyme MBOAT7 (LPIAT1). However, whether restoring MBOAT7 expression in established metabolic dysfunction-associated steatotic liver disease dampens the progression to liver fibrosis and, importantly, the mechanism through which decreased MBOAT7 expression exacerbates MASH fibrosis remain unclear.
Approach and results: We first showed that hepatocyte MBOAT7 restoration in mice with diet-induced steatohepatitis slows the progression to liver fibrosis. Conversely, when hepatocyte-MBOAT7 was silenced in mice with established hepatosteatosis, liver fibrosis but not hepatosteatosis was exacerbated. Mechanistic studies revealed that hepatocyte-MBOAT7 restoration in MASH mice lowered hepatocyte-TAZ (WWTR1), which is known to promote MASH fibrosis. Conversely, hepatocyte-MBOAT7 silencing enhanced TAZ upregulation in MASH. Finally, we discovered that changes in hepatocyte phospholipids due to MBOAT7 loss-of-function promote a cholesterol trafficking pathway that upregulates TAZ and the TAZ-induced profibrotic factor Indian hedgehog (IHH). As evidence for relevance in humans, we found that the livers of individuals with MASH carrying the rs641738-T allele had higher hepatocyte nuclear TAZ, indicating higher TAZ activity and increased IHH mRNA.
Conclusions: This study provides evidence for a novel mechanism linking MBOAT7-LoF to MASH fibrosis, adds new insight into an established genetic locus for MASH, and, given the druggability of hepatocyte TAZ for MASH fibrosis, suggests a personalized medicine approach for subjects at increased risk for MASH fibrosis due to inheritance of variants that lower MBOAT7.
Copyright © 2024 American Association for the Study of Liver Diseases.
Conflict of interest statement
CONFLICTS OF INTEREST
Luca Valenti consults for Novo Nordisk and Pfizer. He is on the speakers’ bureau for Viatris. He received grants from Gilead. The remaining authors have no conflicts to report.
References
-
- Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389–397.e310. - PMC - PubMed
-
- Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627–636. - PubMed
-
- Bohinc BN, Diehl AM. Mechanisms of disease progression in NASH: new paradigms. Clin Liver Dis 2012;16:549–565. - PubMed
-
- Ray K. Resmetirom proves positive for NASH with liver fibrosis. Nat Rev Gastroenterol Hepatol 2024. - PubMed
MeSH terms
Substances
Grants and funding
- R01 DK133694/DK/NIDDK NIH HHS/United States
- R01 DK126779/DK/NIDDK NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- P30 CA013696/CA/NCI NIH HHS/United States
- K99 DK137021/DK/NIDDK NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- U01 DK061732/DK/NIDDK NIH HHS/United States
- R35 HL145228/HL/NHLBI NIH HHS/United States
- P30 DK132710/DK/NIDDK NIH HHS/United States
- P30 DK120531/DK/NIDDK NIH HHS/United States
- U01 DK061730/DK/NIDDK NIH HHS/United States
- U24 DK061730/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
